95 results
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
5 Jun 24
Registered Number 11185179 (England & Wales) Annual Report and financial statements for the year ended 31 December 2023 for Autolus Therapeutics plc
4:35pm
and clinical research and development, and manufacturing and manufacturing process scale-up, and we expect that our ongoing research and development … securities, through public offerings and pursuant to our at-the-equity market facility, through U.K. research and development tax credits and receipts from
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
17 May 24
Results of Operations and Financial Condition
8:27am
in 2023. Research and development expenses increased from $27.4 million to $30.7 million for the three months ended March 31, 2024, compared to the same … Operating expenses: Research and development (30,671) (27,388) General and administrative (18,177) (9,284) Loss on disposal of property and equipment
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
1 Apr 24
Departure of Directors or Certain Officers
7:06am
, having joined the company in 2022. He was previously Chief Medical Officer at Oxford Biomedica and Head of Research and Development and Chief Medical
8-K
AUTL
Autolus Therapeutics plc
1 Apr 24
Departure of Directors or Certain Officers
7:06am
, M.D. to serve as a Class I director of the Company and member of the Research and Development Committee, effective April 1, 2024. Dr. Rao … annual retainer for his service on the Board and a £6,000 annual retainer for his service as a member of the Research and Development Committee. Further
S-3ASR
ct7jce1te4gw9kqd
28 Mar 24
Automatic shelf registration
4:10pm
10-K
EX-10.12
vop37
21 Mar 24
Annual report
4:55pm
10-K
nzctd4vu
21 Mar 24
Annual report
4:55pm
8-K
w2e38jhu2hzc651
21 Mar 24
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:21pm
8-K/A
EX-99.1
oyhurkc4
15 Mar 24
Results of Operations and Financial Condition
4:21pm
8-K
EX-99.2
gosk7li5i2lkexj4
14 Mar 24
Results of Operations and Financial Condition
12:32pm
8-K
EX-99.1
g8mu8udve9dfn616l4
14 Mar 24
Results of Operations and Financial Condition
12:32pm
424B5
umjjg94qawqa2fjfy
9 Feb 24
Prospectus supplement for primary offering
5:15pm
8-K
EX-99.1
7jtj6m9 e9og
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
S-3ASR
0ph3 68o957o78ioji
7 Feb 24
Automatic shelf registration
10:00pm
10-Q
m2ndodqm6z9gd1wu
9 Nov 23
Quarterly report
4:18pm
10-Q
EX-10.1
l3mxh zvhk0t
9 Nov 23
Quarterly report
4:18pm
6-K
EX-99.3
8bndcqregw rys
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.2
hry3mmu9crj80l2 anzp
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.1
6gtgs agga5
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm